US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Relay Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Announces Proposed Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers BCAX RLAY
News headline image
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
News headline image
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Tickers RLAY
< Previous 1 2 Next >